Immunovant
$38.51
58
-$0.11-0.28% 20:00 Today
+$0.00+0%20:20After hours
Statistics
Day High
38.87
Day Low
36.78
52W High
41.23
52W Low
14.32
Volume
685,906
Avg. Volume
1,729,924
Mkt Cap
7.91B
P/E Ratio
-
Dividend Yield
-
Dividend
-
Upcoming
Earnings
6AugExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Q1 2026
Next
-0.76
-0.7
-0.65
-0.59
Expected EPS
-0.618051
Actual EPS
N/A
Financials
-Profit Margin
Unprofitable0Revenue
-505.61MNet Income
Analyst Ratings
44.67Average Price Target
The highest estimate is 62.00.
From 6 ratings within the last 6 months. This is not an investment recommendation.
From 6 ratings within the last 6 months. This is not an investment recommendation.
Buy 67%
Hold 33%
Sell 0%
People Also Follow
This list is based on the watchlists of people on Stock Events who follow IMVT. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
Argen X
ARGX
Mkt Cap54.85B
United Community Banks
UCB
Mkt Cap4.26B
Abbvie
ABBV
Mkt Cap438.31B
AMGEN
AMGN
Mkt Cap196.12B
GSK
GSK
Mkt Cap105.71B
Regeneron Pharmaceuticals
REGN
Mkt Cap69.67B
Novartis
NVS
Mkt Cap293.94B
Bristol-Myers Squibb
BMY
Mkt Cap117.58B
About
Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to advancing novel monoclonal antibody therapies for the treatment of various autoimmune conditions. The company's primary focus is batoclimab, a pioneering, fully human monoclonal antibody. This antibody is engineered to specifically target and block the neonatal fragment crystallizable receptor (FcRn), a key mechanism in certain autoimmune diseases. Batoclimab is currently undergoing Phase IIa clinical evaluations for treating both myasthenia gravis and thyroid eye disease. Additionally, it has commenced Phase II clinical studies for patients suffering from warm autoimmune hemolytic anemia. Established in 2018, Immunovant operates from its headquarters in New York, New York, functioning as a subsidiary under the umbrella of Roivant Sciences Ltd.
Show more...
CEO
Dr. Frank M. Torti M.B.A., M.D.
Employees
315
Country
United States
ISIN
US45258J1025
Listings
0 Comments
Share your thoughts
FAQ
What is Immunovant stock price today?▼
The current price of IMVT is $38.51 USD — it has decreased by -0.28% in the past 24 hours. Watch Immunovant stock price performance more closely on the chart.
What is Immunovant stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Immunovant stocks are traded under the ticker IMVT.
Is Immunovant stock price growing?▼
IMVT stock has fallen by -3.94% compared to the previous week, the month change is a -0.72% fall, over the last year Immunovant has showed a +145.13% increase.
What is Immunovant market cap?▼
Today Immunovant has the market capitalization of 7.91B
When is the next Immunovant earnings date?▼
Immunovant is going to release the next earnings report on August 06, 2026.
What were Immunovant earnings last quarter?▼
IMVT earnings for the last quarter are -0.73 USD per share, whereas the estimation was -0.59 USD resulting in a -23.31% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Immunovant revenue for the last year?▼
Immunovant revenue for the last year amounts to 0 USD.
What is Immunovant net income for the last year?▼
IMVT net income for the last year is -505.61M USD.
How many employees does Immunovant have?▼
As of August 03, 2026, the company has 315 employees.
In which sector is Immunovant located?▼
Immunovant operates in the Health & Wellness sector.
When did Immunovant complete a stock split?▼
Immunovant has not had any recent stock splits.
Where is Immunovant headquartered?▼
Immunovant is headquartered in Durham, United States.